Sttr phase II
Ended Definitive Contract Awarded Last action
- Contract number
- W911QY20C0099
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $1,499,004
Award facts
- Contract value 100% obligated
- $1,499,004.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Research Development and Engineering Command Army Materiel Command, Department of Defense
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
- Research
- STTR Phase II
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Change Order | $499,970 | |
| Funding Only Action | $499,517 | |
| Other Administrative Action | $0 | |
| Original award | $499,517 |
About this award
The U.S. Army's Research, Development and Engineering Command awarded a Small Business Technology Transfer (STTR) Phase II contract to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology firm specializing in antibody-based therapeutics and medical countermeasures against infectious diseases. The $1.5 million definitive contract, awarded July 28, 2020, with completion targeted for February 28, 2023, operates under a cost-plus-fixed-fee structure and includes a total small business set-aside designation. Contract administration was transferred from the Army Contracting Command–Aberdeen Proving Ground, Natick Division to the Army Contracting Command–Aberdeen Proving Ground, Edgewood Division during the performance period.
The STTR Phase II designation indicates that this contract represents the second phase of development for a small business innovation research effort, likely building upon a successfully completed Phase I feasibility study. Mapp Biopharmaceutical's established track record of developing medical countermeasures against biological threats—including prior federal funding for therapeutics targeting Ebola, Sudan, Marburg, and other infectious pathogens—positions the company as a strategic partner for the Army's medical preparedness objectives. This award reflects the government's commitment to leveraging small business innovation capabilities to advance critical medical countermeasures aligned with national defense and public health security priorities.
Quick answers
Who was awarded contract W911QY20C0099?
W911QY20C0099 was awarded to Mapp Biopharmaceutical, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on July 28, 2020.
How much is contract W911QY20C0099 worth?
The government has obligated $1,499,004 on W911QY20C0099.
Which agency awarded contract W911QY20C0099?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY20C0099, with funding from Research Development and Engineering Command (Army Materiel Command).
Was contract W911QY20C0099 competed?
The extent of competition for W911QY20C0099 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award